<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="doi: 10.3389/fmicb.2020.00612 : Microbiology: Original Research Depletion of Host and" exact="Viral" post="Sphingomyelin Impairs Influenza Virus Infection AudiAmani12SoudaniNadia123DbaiboGhassan245*ZaraketHassan12*[], 1Department of Experimental"/>
 <result pre="Research Depletion of Host and Viral Sphingomyelin Impairs Influenza Virus" exact="Infection" post="AudiAmani12SoudaniNadia123DbaiboGhassan245*ZaraketHassan12*[], 1Department of Experimental Pathology, Immunology and Microbiology, Faculty"/>
 <result pre="1Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine," exact="American" post="University of BeirutBeirutLebanon[], 2Center for Infectious Diseases Research, Faculty"/>
 <result pre="Microbiology, Faculty of Medicine, American University of BeirutBeirutLebanon[], 2Center for" exact="Infectious" post="Diseases Research, Faculty of Medicine, American University of BeirutBeirutLebanon[],"/>
 <result pre="Faculty of Medicine, American University of BeirutBeirutLebanon[], 2Center for Infectious" exact="Diseases" post="Research, Faculty of Medicine, American University of BeirutBeirutLebanon[], 3Doctoral"/>
 <result pre="of BeirutBeirutLebanon[], 2Center for Infectious Diseases Research, Faculty of Medicine," exact="American" post="University of BeirutBeirutLebanon[], 3Doctoral School of Science and Technology,"/>
 <result pre="UniversityBeirutLebanon[], 4Department of Pediatrics and Adolescent Medicine, Faculty of Medicine," exact="American" post="University of Beirut Medical CenterBeirutLebanon[], 5Department of Biochemistry and"/>
 <result pre="CenterBeirutLebanon[], 5Department of Biochemistry and Molecular Genetics, Faculty of Medicine," exact="American" post="University of BeirutBeirutLebanon Edited by: Jason Kindrachuk, University of"/>
 <result pre="terms. Abstract Influenza A virus (IAV) is a major human" exact="respiratory" post="pathogen causing annual epidemics as well as periodic pandemics."/>
 <result pre="major human respiratory pathogen causing annual epidemics as well as" exact="periodic" post="pandemics. A complete understanding of the virus pathogenesis and"/>
 <result pre="pathogen causing annual epidemics as well as periodic pandemics. A" exact="complete" post="understanding of the virus pathogenesis and host factors involved"/>
 <result pre="of the virus pathogenesis and host factors involved in the" exact="viral" post="lifecycle is crucial for developing novel therapeutic approaches. Sphingomyelin"/>
 <result pre="hydrolysis on IAV propagation. Depleting plasma membrane SM by exogenous" exact="bacterial" post="SMase (bSMase) impaired virus infection and reduced virus entry,"/>
 <result pre="Depleting plasma membrane SM by exogenous bacterial SMase (bSMase) impaired" exact="virus infection" post="and reduced virus entry, whereas exogenous SM enhanced infection."/>
 <result pre="plasma membrane SM by exogenous bacterial SMase (bSMase) impaired virus" exact="infection" post="and reduced virus entry, whereas exogenous SM enhanced infection."/>
 <result pre="affect IAV infection. Similarly, virus replication was not impaired in" exact="Niemann-Pick disease" post="type A (NPA) cells, which lack functional ASMase. IAV"/>
 <result pre="IAV infection. Similarly, virus replication was not impaired in Niemann-Pick" exact="disease" post="type A (NPA) cells, which lack functional ASMase. IAV"/>
 <result pre="infection. Similarly, virus replication was not impaired in Niemann-Pick disease" exact="type A" post="(NPA) cells, which lack functional ASMase. IAV infection in"/>
 <result pre="disease type A (NPA) cells, which lack functional ASMase. IAV" exact="infection" post="in A549 cells was associated with suppression of ASMase"/>
 <result pre="6 h post-infection. Our data reveals that intact cellular and" exact="viral" post="envelope SM is required for efficient IAV infection. Therefore,"/>
 <result pre="can be a potential target for therapeutic intervention against influenza" exact="virus infection." post="influenza virus lipid rafts sphingomyelin acid sphingomyelinase viral envelope"/>
 <result pre="influenza virus infection. influenza virus lipid rafts sphingomyelin acid sphingomyelinase" exact="viral" post="envelope plasma membrane bacterial sphingomyelinase Funding American University of"/>
 <result pre="virus lipid rafts sphingomyelin acid sphingomyelinase viral envelope plasma membrane" exact="bacterial" post="sphingomyelinase Funding American University of Beirut10.13039/100007688 fig-count: table-count: equation-count:"/>
 <result pre="sphingomyelin acid sphingomyelinase viral envelope plasma membrane bacterial sphingomyelinase Funding" exact="American" post="University of Beirut10.13039/100007688 fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
 <result pre="due to the significant morbidity and mortality associated with the" exact="disease" post="(Lee et al., 2018). Recent studies showed that respiratory"/>
 <result pre="the disease (Lee et al., 2018). Recent studies showed that" exact="respiratory" post="infections-associated with seasonal influenza viruses are responsible for 290,000"/>
 <result pre="the Orthomyxoviridae family. The virus is made up of a" exact="viral" post="envelope, a matrix layer, and a central core with"/>
 <result pre="Coloma et al., 2009; Zheng and Tao, 2013). During its" exact="infectious" post="cycle, influenza A virus (IAV) has to cross the"/>
 <result pre="Additionally, sphingolipids have been implicated during different aspects of the" exact="viral" post="life cycles including attachment (Puri et al., 2004; Rawat"/>
 <result pre="As such, they are considered a promising therapeutic target against" exact="viral" post="infections (Yager and Konan, 2019). Several studies have demonstrated"/>
 <result pre="such, they are considered a promising therapeutic target against viral" exact="infections" post="(Yager and Konan, 2019). Several studies have demonstrated a"/>
 <result pre="Sphingosine-1-phosphate- (S1P) metabolizing enzymes have been shown to modulate influenza" exact="infection" post="in vitro and in vivo (Seo et al., 2010,"/>
 <result pre="2013; Xia et al., 2018). Sphingosine kinase 1 (SK1) enhances" exact="viral" post="replication through regulating viral RNA synthesis and export of"/>
 <result pre="2018). Sphingosine kinase 1 (SK1) enhances viral replication through regulating" exact="viral" post="RNA synthesis and export of nuclear viral ribonucleoprotein complex"/>
 <result pre="replication through regulating viral RNA synthesis and export of nuclear" exact="viral" post="ribonucleoprotein complex (Seo et al., 2013). Glucosylceramidase is critical"/>
 <result pre="ribonucleoprotein complex (Seo et al., 2013). Glucosylceramidase is critical during" exact="infection" post="by controlling the successful trafficking of influenza virus to"/>
 <result pre="de novo ceramide plays a protective antiviral role against IAV" exact="infection" post="(Soudani et al., 2019). Furthermore, exogenous short-chained ceramide enhances"/>
 <result pre="SM and its hydrolyzing enzyme ASMase were implicated during Ebola" exact="virus infection" post="(Miller et al., 2012). Recently, alphaherpesviruses were shown to"/>
 <result pre="and its hydrolyzing enzyme ASMase were implicated during Ebola virus" exact="infection" post="(Miller et al., 2012). Recently, alphaherpesviruses were shown to"/>
 <result pre="ASMase during entry into host cells (Pastenkos et al., 2018)." exact="Japanese encephalitis" post="virus attachment and entry into target cells was shown"/>
 <result pre="during entry into host cells (Pastenkos et al., 2018). Japanese" exact="encephalitis" post="virus attachment and entry into target cells was shown"/>
 <result pre="its substrate SM in IAV infection. We found that genetic" exact="deficiency" post="or pharmacological inhibition of ASMase does not prevent IAV"/>
 <result pre="inhibition of ASMase does not prevent IAV infection. However, IAV" exact="infection" post="was attenuated by the depletion of membrane SM and"/>
 <result pre="exogenous SM. SM depletion of the plasma membrane or the" exact="viral" post="envelope impaired IAV attachment and internalization. These results demonstrate"/>
 <result pre="results demonstrate that IAV does not require ASMase activity for" exact="infection" post="and that intact SM in both cell membrane and"/>
 <result pre="infection and that intact SM in both cell membrane and" exact="viral" post="envelope is essential for efficient IAV entry. Materials and"/>
 <result pre="canine kidney cells (MDCK) were obtained from Biodefense and Emerging" exact="Infections" post="Research Resources Repository (BEI Resources), human alveolar lung carcinoma"/>
 <result pre="and Emerging Infections Research Resources Repository (BEI Resources), human alveolar" exact="lung carcinoma" post="(A549) were obtained from ATCC (Manassas, VA, United States),"/>
 <result pre="Emerging Infections Research Resources Repository (BEI Resources), human alveolar lung" exact="carcinoma" post="(A549) were obtained from ATCC (Manassas, VA, United States),"/>
 <result pre="(A549) were obtained from ATCC (Manassas, VA, United States), healthy" exact="primary" post="human fibroblasts (GM00038) and Niemann-Pick disease type A (NPA)"/>
 <result pre="(Manassas, VA, United States), healthy primary human fibroblasts (GM00038) and" exact="Niemann-Pick disease" post="type A (NPA) fibroblasts (GM00112 and GM13205) were from"/>
 <result pre="VA, United States), healthy primary human fibroblasts (GM00038) and Niemann-Pick" exact="disease" post="type A (NPA) fibroblasts (GM00112 and GM13205) were from"/>
 <result pre="United States), healthy primary human fibroblasts (GM00038) and Niemann-Pick disease" exact="type A" post="(NPA) fibroblasts (GM00112 and GM13205) were from Coriell Cell"/>
 <result pre="Resources. The viruses were propagated on MDCK cells supplemented with" exact="viral infection" post="medium (VIM) consisting of 1X minimal essential media (10X"/>
 <result pre="The viruses were propagated on MDCK cells supplemented with viral" exact="infection" post="medium (VIM) consisting of 1X minimal essential media (10X"/>
 <result pre="(Sigma) just before addition to the infected MDCK cells. Virus" exact="Infections" post="A549 cells seeded in a 12-well tissue culture plate"/>
 <result pre="magnesium (PBS+) and incubated with VIM in the presence or" exact="absence of" post="the tested drug. The cells were then infected with"/>
 <result pre="of the virus diluted in VIM in the presence or" exact="absence of" post="the drug at 37°C for 1 h. Afterward, cells"/>
 <result pre="twice with mild acidic PBS+ (pH 5) to remove unbound" exact="viral" post="particles. Subsequently, cells were incubated with pre-warmed VIM containing"/>
 <result pre="μg/ml TPCK-treated trypsin (Sigma) at 37°C in the presence or" exact="absence of" post="the drug and the virus yield was determined by"/>
 <result pre="and an aliquot containing 30 μg protein (determined by DCTM" exact="Protein" post="Assay Kit from BIO-RAD). The sample protein was analyzed"/>
 <result pre="A12220) using the two-step process based on the manufacturer’s instructions." exact="Total" post="Viral RNA Quantification by RT-PCR The supernatant of bacterial"/>
 <result pre="using the two-step process based on the manufacturer’s instructions. Total" exact="Viral" post="RNA Quantification by RT-PCR The supernatant of bacterial SMase"/>
 <result pre="instructions. Total Viral RNA Quantification by RT-PCR The supernatant of" exact="bacterial" post="SMase (bSMase)-treated and untreated cells was collected, followed by"/>
 <result pre="bacterial SMase (bSMase)-treated and untreated cells was collected, followed by" exact="total" post="viral RNA extraction using PureLink Viral RNA/DNA Minikit (Invitrogen)"/>
 <result pre="SMase (bSMase)-treated and untreated cells was collected, followed by total" exact="viral" post="RNA extraction using PureLink Viral RNA/DNA Minikit (Invitrogen) according"/>
 <result pre="was collected, followed by total viral RNA extraction using PureLink" exact="Viral" post="RNA/DNA Minikit (Invitrogen) according to the manufacturer’s protocol. Quantitative"/>
 <result pre="gene (IAV) (World Health Organization, 2018). One-Step RT-PCR AgPath-ID (Thermo" exact="Fisher" post="Scientific) was used to amplify the target according to"/>
 <result pre="s and 55°C for 1 min. In each sample, the" exact="viral" post="gene copy number was assessed using a standard curve"/>
 <result pre="for 2 h and then washed twice with HBSS+ before" exact="infection" post="with either PR8 or Cal07. Virus yields in bSMase-treated"/>
 <result pre="plaque assay and RT-PCR as described above. For depletion of" exact="viral" post="envelope SM, PR8 high titer stock was mixed with"/>
 <result pre="incubated for 1 h with Alexa Flour 488 goat anti-mouse" exact="secondary" post="antibody (Thermofisher Scientific, A11001) at 1:250 in 1% BSA."/>
 <result pre="with a fluoroshield mounting medium containing DAPI. The images were" exact="acquired" post="with a 40x or 63x oil objective lens, as"/>
 <result pre="untreated cells. (D–G) The effect of SM depletion on IAV" exact="infection" post="was determined by the plaque assay (D–F) or RT-PCR"/>
 <result pre="increasing bSMase concentrations or vehicle for 2 h followed by" exact="infection" post="with either PR8 at 1 MOI (D,G) and 0.01"/>
 <result pre="and 0.01 MOI (E) or Cal07 at 1 MOI (F)." exact="Viral" post="titers were then determined using the plaque assay at"/>
 <result pre="and plotted relative to the vehicle-treated cells. Variation in PR8" exact="total" post="viral RNA in the supernatant of bSMase-treated and untreated"/>
 <result pre="plotted relative to the vehicle-treated cells. Variation in PR8 total" exact="viral" post="RNA in the supernatant of bSMase-treated and untreated cells"/>
 <result pre="24 hpi (Figure 1D). To verify whether the suppression in" exact="virus infection" post="by SM depletion is specific for IAV PR8, we"/>
 <result pre="hpi (Figure 1D). To verify whether the suppression in virus" exact="infection" post="by SM depletion is specific for IAV PR8, we"/>
 <result pre="PR8, we examined the effect of bSMase treatment on the" exact="infection" post="with a contemporary A/H1N1pdm09 strain (Cal07). A549 cells were"/>
 <result pre="of the virus propagated in these cells, we quantified the" exact="total" post="viral RNA in the supernatant of bSMase-treated (1 U/ml)"/>
 <result pre="the virus propagated in these cells, we quantified the total" exact="viral" post="RNA in the supernatant of bSMase-treated (1 U/ml) and"/>
 <result pre="Similar to the results obtained by using plaque assay, the" exact="total" post="viral RNA was significantly reduced in the supernatant of"/>
 <result pre="to the results obtained by using plaque assay, the total" exact="viral" post="RNA was significantly reduced in the supernatant of bSMase-treated"/>
 <result pre="and untreated cells. (B) The effect of SM on IAV" exact="infection" post="was studied. A549 cells were pretreated with 50 μM"/>
 <result pre="hypothesize that SM is essential for early steps in the" exact="viral" post="life cycle. Therefore, we assessed IAV attachment and internalization"/>
 <result pre="Alexa Fluor 488 conjugated anti-mouse antibody (green) (A,B). Alternatively, after" exact="viral" post="adsorption at 4°C for 1 h, the cells were"/>
 <result pre="3C,D). These results were confirmed by real-time PCR of the" exact="total" post="viral RNA (data not shown). Therefore, SM is implicated"/>
 <result pre="These results were confirmed by real-time PCR of the total" exact="viral" post="RNA (data not shown). Therefore, SM is implicated during"/>
 <result pre="entry step of IAV infection. ASMase Is Dispensable for IAV" exact="Infection" post="Some viruses which utilize lipid rafts for entry require"/>
 <result pre="cytotoxicity on A549 cells at concentrations of 25 μM and" exact="lower" post="upon treatment for 24 h (Figure 4A) and up"/>
 <result pre="cells (Figure 4C). FIGURE 4 ASMase is dispensable for IAV" exact="infection" post="(A,B) Cytotoxicity of desipramine (Des) in A549 cells was"/>
 <result pre="Assay Kit. (D) The impact of ASMase inhibition on IAV" exact="infection" post="was assessed using the plaque assay and plotted relative"/>
 <result pre="PR8 (1 MOI) for 1 h in the presence or" exact="absence of" post="the inhibitor. Cells were then incubated with or without"/>
 <result pre="incubated with or without the drug for 24 hpi, and" exact="viral" post="titers were determined using the plaque assay. (E) Primary"/>
 <result pre="and viral titers were determined using the plaque assay. (E)" exact="Primary" post="human fibroblasts deficient in ASMase activity (GM00112 and GM13205)"/>
 <result pre="deficient in ASMase activity (GM00112 and GM13205) and normal human" exact="primary" post="fibroblasts (GM00038) were infected with PR8 at 1 MOI"/>
 <result pre="infected with PR8 at 1 MOI for the indicated durations." exact="Normal" post="human primary fibroblasts were used as a control. The"/>
 <result pre="PR8 at 1 MOI for the indicated durations. Normal human" exact="primary" post="fibroblasts were used as a control. The virus yield"/>
 <result pre="To eliminate the possibility that residual ASMase activity due to" exact="incomplete" post="inhibition (Figure 4C) might be sufficient for efficient viral"/>
 <result pre="to incomplete inhibition (Figure 4C) might be sufficient for efficient" exact="viral" post="replication, we assessed IAV replication in NPA fibroblasts, which"/>
 <result pre="replication, we assessed IAV replication in NPA fibroblasts, which have" exact="total" post="loss of ASMase activity. Two NPA cell-lines (GM00112 and"/>
 <result pre="that ASMase activity is not required for IAV infection. IAV" exact="Infection" post="Restricts ASMase Activity at Later Time-Points Post-infection The finding"/>
 <result pre="that IAV significantly inhibits ASMase activity at later stages of" exact="infection" post="to possibly preserve SM for subsequent infection cycles. FIGURE"/>
 <result pre="later stages of infection to possibly preserve SM for subsequent" exact="infection" post="cycles. FIGURE 5 IAV infection restricts ASMase activity at"/>
 <result pre="possibly preserve SM for subsequent infection cycles. FIGURE 5 IAV" exact="infection" post="restricts ASMase activity at later time-points post-infection. A549 cells"/>
 <result pre="a P-value &amp;lt; 0.01). Next, we examined the effect of" exact="viral" post="envelope SM depletion on IAV attachment and internalization. A549"/>
 <result pre="to the vehicle-treated virus (Figures 7C,D). These findings indicate that" exact="viral" post="envelope SM-depletion reduces both binding and internalization of IAV,"/>
 <result pre="Alexa Fluor 488 conjugated anti-mouse antibody (green) (A,B). Alternatively, following" exact="viral" post="adsorption, the cells were placed at 37°C for an"/>
 <result pre="fully explored. In this study, we demonstrated that efficient IAV" exact="infection" post="is dependent on intact SM in the plasma membrane"/>
 <result pre="in the plasma membrane of the host cell and the" exact="viral" post="envelope, specifically at the virus entry step, while ASMase"/>
 <result pre="during IAV infection, we treated cells with exogenous bSMase before" exact="infection" post="to deplete membrane SM. Exogenously applied bSMase, specifically hydrolyzes"/>
 <result pre="shown to impair multiplication of viruses that require SM during" exact="infection" post="such as Ebola virus, Japanese encephalitis virus, Rubella virus,"/>
 <result pre="viruses that require SM during infection such as Ebola virus," exact="Japanese encephalitis" post="virus, Rubella virus, and porcine alphaherpesvirus (Miller et al.,"/>
 <result pre="that require SM during infection such as Ebola virus, Japanese" exact="encephalitis" post="virus, Rubella virus, and porcine alphaherpesvirus (Miller et al.,"/>
 <result pre="was found to enhance IAV replication. The modest enhancement of" exact="virus infection" post="may be due to the already SM-saturated cellular membrane"/>
 <result pre="found to enhance IAV replication. The modest enhancement of virus" exact="infection" post="may be due to the already SM-saturated cellular membrane"/>
 <result pre="al., 2018). Since some viruses that utilize lipid rafts during" exact="infection" post="show a requirement for ASMase during infection (Steinhart et"/>
 <result pre="lipid rafts during infection show a requirement for ASMase during" exact="infection" post="(Steinhart et al., 1984; Grassme, 2005; Miller et al.,"/>
 <result pre="Miller et al., 2012), we assessed the association between IAV" exact="infection" post="and endogenous ASMase. We examined the effect of pharmacological"/>
 <result pre="ASMase. We examined the effect of pharmacological ASMase-inhibition and ASMase-genetic" exact="deficiency" post="on IAV infection. We found that, unlike Ebola virus,"/>
 <result pre="have a mutation in the SMPD1 gene that results in" exact="total" post="loss of enzyme activity (Levade et al., 1986). Unlike"/>
 <result pre="et al., 1986). Unlike rhinovirus which induces ASMase activation during" exact="infection" post="(Grassme, 2005), ASMase was not activated in IAV-infected cells"/>
 <result pre="and Griffin, 2006). The decrease in ASMase activity observed during" exact="infection" post="may be virus-induced to maintain the SM membrane pools"/>
 <result pre="Trani et al., 2007; Kornhuber et al., 2010). These compounds" exact="diffuse" post="through endosomal membranes and become protonated, thus increasing the"/>
 <result pre="1991; Di Trani et al., 2007). Besides, amantadine blocks the" exact="viral" post="M2 channel and subsequently inhibits the uncoating step of"/>
 <result pre="that ASMase is dispensable for its replication. Sphingomyelin in the" exact="viral" post="envelope was shown to be essential for some viruses."/>
 <result pre="viruses. For example, depletion of SM from the envelope of" exact="hepatitis" post="C virus and bovine herpesvirus-1 impaired their infectivity (Aizaki"/>
 <result pre="cholesterol, and phosphatidylcholine (Scheiffele et al., 1999). HA and NA" exact="viral" post="glycoproteins preferentially concentrate in those lipid microdomains during assembly"/>
 <result pre="these glycoproteins also concentrate within the lipid rafts in the" exact="viral" post="envelope. In our study, the depletion of SM in"/>
 <result pre="reduced virus infectivity without affecting the HA levels of the" exact="viral" post="envelope. Both cell attachment and internalization of SM-depleted IAV"/>
 <result pre="(Takeda et al., 2003). It is also possible that disrupting" exact="viral" post="SM might interfere with the barrier properties of the"/>
 <result pre="Supporting the latter hypothesis, bSMase treatment was shown to abolish" exact="rubella" post="virus E1/E2-mediated membrane fusion (Otsuki et al., 2018). In"/>
 <result pre="summary, our present work provides strong evidence that cellular and" exact="viral" post="SM is required for efficient IAV infection, particularly during"/>
 <result pre="investigations are needed to determine the precise mechanisms by which" exact="viral" post="and cellular SM mediate IAV entry. Our findings provide"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="Plan (MPP) and the University Research Board (URB) of the" exact="American" post="University of Beirut. We thank Drs. Jamilah Borjac and"/>
 <result pre="al. (2008). Critical role of virion-associated cholesterol and sphingolipid in" exact="hepatitis" post="C virus infection.J. Virol.825715–5724. 10.1128/JVI.02530-0718367533 ChernomordikL. V.LeikinaE.FrolovV.BronkP.ZimmerbergJ. (1997). An"/>
 <result pre="associated with divergent inhibitory effects of chloroquine on human and" exact="avian influenza" post="A viruses.Virol. J.4:39. 10.1186/1743-422X-4-3917477867 DrakeM. J.BrennanB.BrileyK.BartS. M.ShermanE.SzemielA. M.et al."/>
 <result pre="(2017). A role for glycolipid biosynthesis in severe fever with" exact="thrombocytopenia" post="syndrome virus entry.PLoS Pathog.13:e1006316. 10.1371/journal.ppat.100631628388693 DrewsK.CalgiM. P.HarrisonW. C.DrewsC. M.Costa-PinheiroP.ShawJ."/>
 <result pre="A role for glycolipid biosynthesis in severe fever with thrombocytopenia" exact="syndrome" post="virus entry.PLoS Pathog.13:e1006316. 10.1371/journal.ppat.100631628388693 DrewsK.CalgiM. P.HarrisonW. C.DrewsC. M.Costa-PinheiroP.ShawJ. J."/>
 <result pre="P.HarrisonW. C.DrewsC. M.Costa-PinheiroP.ShawJ. J. P.et al. (2019). Glucosylceramidase maintains influenza" exact="virus infection" post="by regulating endocytosis.J. Virol.93:e00017-19. 10.1128/JVI.00017-1930918081 EdingerT. O.PohlM. O.StertzS. (2014)."/>
 <result pre="C.DrewsC. M.Costa-PinheiroP.ShawJ. J. P.et al. (2019). Glucosylceramidase maintains influenza virus" exact="infection" post="by regulating endocytosis.J. Virol.93:e00017-19. 10.1128/JVI.00017-1930918081 EdingerT. O.PohlM. O.StertzS. (2014)."/>
 <result pre="and membrane activity.FEBS Lett.53138–46. 10.1016/s0014-5793(02)03482-812401200 GrassmeH. (2005). Rhinoviruses infect human" exact="epithelial" post="cells via Ceramide-enriched membrane platforms.J. Biol. Chem.28026256–26262. 10.1074/jbc.M50083520015888438 HannunY."/>
 <result pre="HeM.GuoS.RenJ.LiZ. (2016). In situ characterizing membrane lipid phenotype of human" exact="lung cancer" post="cell lines using mass spectrometry profiling.J. Cancer7810–816. 10.7150/jca.1431027162539 HidariK."/>
 <result pre="(2016). In situ characterizing membrane lipid phenotype of human lung" exact="cancer" post="cell lines using mass spectrometry profiling.J. Cancer7810–816. 10.7150/jca.1431027162539 HidariK."/>
 <result pre="HuangH.TongT.-T.YauL.-F.ChenC.-Y.MiJ.-N.WangJ.-R.et al. (2018). LC-MS based sphingolipidomic study on A549 human" exact="lung adenocarcinoma" post="cell line and its taxol-resistant strain.BMC Cancer18:799. 10.1186/s12885-018-4714-x30089463 HuprikarJ.RabinowitzS."/>
 <result pre="al. (2018). LC-MS based sphingolipidomic study on A549 human lung" exact="adenocarcinoma" post="cell line and its taxol-resistant strain.BMC Cancer18:799. 10.1186/s12885-018-4714-x30089463 HuprikarJ.RabinowitzS."/>
 <result pre="M.SánchezM. P.LedesmaM. D.SobrinoF.et al. (2016). Host sphingomyelin increases West Nile" exact="virus infection" post="in vivo.J. Lipid Res.57422–432. 10.1194/jlr.M06421226764042 MillerM. E.AdhikaryS.KolokoltsovA. A.DaveyR. A."/>
 <result pre="P.LedesmaM. D.SobrinoF.et al. (2016). Host sphingomyelin increases West Nile virus" exact="infection" post="in vivo.J. Lipid Res.57422–432. 10.1194/jlr.M06421226764042 MillerM. E.AdhikaryS.KolokoltsovA. A.DaveyR. A."/>
 <result pre="lysosomotropic compounds.Toxicol. Vitro25715–723. 10.1016/j.tiv.2010.12.01021184822 NgC. G.GriffinD. E. (2006). Acid sphingomyelinase" exact="deficiency" post="increases susceptibility to fatal alphavirus encephalomyelitis.J. Virol.8010989–10999. 10.1128/JVI.01154-0616943298 NguyenD."/>
 <result pre="Vitro25715–723. 10.1016/j.tiv.2010.12.01021184822 NgC. G.GriffinD. E. (2006). Acid sphingomyelinase deficiency increases" exact="susceptibility to" post="fatal alphavirus encephalomyelitis.J. Virol.8010989–10999. 10.1128/JVI.01154-0616943298 NguyenD. H.HildrethJ. E. K."/>
 <result pre="NguyenD. H.HildrethJ. E. K. (2000). Evidence for budding of human" exact="immunodeficiency" post="virus type 1 selectively from glycolipid-enriched membrane lipid rafts.J."/>
 <result pre="E. K. (2000). Evidence for budding of human immunodeficiency virus" exact="type 1" post="selectively from glycolipid-enriched membrane lipid rafts.J. Virol.743264–3272. 10.1128/jvi.74.7.3264-3272.200010708443 NievaJ."/>
 <result pre="W.et al. (2004). An inhibitor of glycosphingolipid metabolism blocks HIV-1" exact="infection" post="of primary T-cells.AIDS18849–858. 10.1097/00002030-200404090-0000215060432 RawatS. S.GalloS. A.EatonJ.MartinT. D.AblanS.KewalRamaniV. N.et"/>
 <result pre="(2004). An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of" exact="primary" post="T-cells.AIDS18849–858. 10.1097/00002030-200404090-0000215060432 RawatS. S.GalloS. A.EatonJ.MartinT. D.AblanS.KewalRamaniV. N.et al. (2004)."/>
 <result pre="primary T-cells.AIDS18849–858. 10.1097/00002030-200404090-0000215060432 RawatS. S.GalloS. A.EatonJ.MartinT. D.AblanS.KewalRamaniV. N.et al. (2004)." exact="Elevated" post="expression of GM3 in receptor-bearing targets confers resistance to"/>
 <result pre="expression of GM3 in receptor-bearing targets confers resistance to human" exact="immunodeficiency" post="virus type 1 fusion.J. Virol.787360–7368. 10.1128/JVI.78.14.7360-7368.200415220409 RossmanJ. S.LambR. A."/>
 <result pre="GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus" exact="type 1" post="fusion.J. Virol.787360–7368. 10.1128/JVI.78.14.7360-7368.200415220409 RossmanJ. S.LambR. A. (2011). Influenza virus"/>
 <result pre="SeoY.-J.BlakeC.AlexanderS.HahmB. (2010). Sphingosine 1-phosphate-metabolizing enzymes control influenza virus propagation and" exact="viral" post="cytopathogenicity.J. Virol.848124–8131. 10.1128/JVI.00510-1020519401 SeoY.-J.PritzlC. J.VijayanM.BombK.McClainM. E.AlexanderS.et al. (2013). Sphingosine"/>
 <result pre="Sphingosine kinase 1 serves as a pro-viral factor by regulating" exact="Viral" post="RNA synthesis and nuclear export of viral ribonucleoprotein complex"/>
 <result pre="factor by regulating Viral RNA synthesis and nuclear export of" exact="viral" post="ribonucleoprotein complex upon influenza virus infection.PLoS One8:e0075005. 10.1371/journal.pone.007500524137500 ShivannaV.KimY.ChangK.-O."/>
 <result pre="10.1128/JVI.00053-1930700605 SteinhartW. L.BuschJ. S.OettgenJ. P.HowlandJ. L. (1984). Sphingolipid metabolism during" exact="infection" post="of human fibroblasts by herpes simplex virus type 1.Intervirology2170–76."/>
 <result pre="L. (1984). Sphingolipid metabolism during infection of human fibroblasts by" exact="herpes" post="simplex virus type 1.Intervirology2170–76. 10.1159/0001495046321394 SteinhauerD. A.WhartonS. A.SkehelJ. J.WileyD."/>
 <result pre="Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient" exact="viral" post="fusion.Proc. Natl. Acad. Sci. U.S.A.10014610–14617. 10.1073/pnas.223562010014561897 TaniguchiM.TasakiT.NinomiyaH.UedaY.KuremotoK.-I.MitsutakeS.et al. (2016)."/>
 <result pre="generated by sphingomyelin synthase 1 is involved in attachment and" exact="infection" post="with Japanese encephalitis virus.Sci. Rep.6:37829. 10.1038/srep3782927892528 TannerL. B.ChngC.GuanX. L.LeiZ.RozenS."/>
 <result pre="sphingomyelin synthase 1 is involved in attachment and infection with" exact="Japanese encephalitis" post="virus.Sci. Rep.6:37829. 10.1038/srep3782927892528 TannerL. B.ChngC.GuanX. L.LeiZ.RozenS. G.WenkM. R. (2014)."/>
 <result pre="synthase 1 is involved in attachment and infection with Japanese" exact="encephalitis" post="virus.Sci. Rep.6:37829. 10.1038/srep3782927892528 TannerL. B.ChngC.GuanX. L.LeiZ.RozenS. G.WenkM. R. (2014)."/>
 <result pre="and endocytosis of influenza a virus.Viruses10:650. 10.3390/v1011065030453689 VijayanM.HahmB. (2014). Influenza" exact="viral" post="manipulation of sphingolipid metabolism and signaling to modulate host"/>
 <result pre="the amantadine block.J. Virol.675585–5594. 10.1128/jvi.67.9.5585-5594.19937688826 WengL.HirataY.AraiM.KoharaM.WakitaT.WatashiK.et al. (2010). Sphingomyelin activates" exact="hepatitis" post="C virus RNA polymerase in a genotype-specific manner.J. Virol.8411761–11770."/>
 <result pre="online at: https://www.who.int/influenza/gisrs_laboratory/molecular_diagnosis/en/(accessed April 08, 2020). XiaC.SeoY.-J.StudstillC. J.VijayanM.WolfJ. J.HahmB. (2018)." exact="Transient" post="inhibition of sphingosine kinases confers protection to influenza A"/>
</results>
